Metastasectomy for metastatic melanoma in the era of effective systemic therapy
- 23 May 2023
- journal article
- research article
- Published by Elsevier in The American Journal of Surgery
- Vol. 231, 65-69
Abstract
No abstract availableKeywords
This publication has 11 references indexed in Scilit:
- The Landmark Series: MSLT-1, MSLT-2 and DeCOG (Management of Lymph Nodes)Annals of Surgical Oncology, 2019
- Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 studyThe Lancet Oncology, 2019
- Impact of Effective Systemic Therapy on Metastasectomy in Stage IV Melanoma: A Matched-Pair AnalysisAnnals of Surgical Oncology, 2019
- Combined Nivolumab and Ipilimumab or Monotherapy in Untreated MelanomaNew England Journal of Medicine, 2015
- Chemotherapy in the management of advanced cutaneous malignant melanomaClinics in Dermatology, 2013
- Metastasectomy for Distant Metastatic Melanoma: Analysis of Data from the First Multicenter Selective Lymphadenectomy Trial (MSLT-I)Annals of Surgical Oncology, 2012
- Improved Survival with Vemurafenib in Melanoma with BRAF V600E MutationNew England Journal of Medicine, 2011
- A phase 2 trial of complete resection for stage IV melanomaCancer, 2011
- Improved Survival with Ipilimumab in Patients with Metastatic MelanomaNew England Journal of Medicine, 2010
- Surgical treatment of metastatic melanomaThe American Journal of Surgery, 1998